A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Clinical trial NCT02257567 · COMPLETED
Trial details
- NCT number
- NCT02257567
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-15
- Primary completion
- 2021-10-21
- Enrollment
- 331
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.